SCHEMBL21612928

SCHEMBL21612928

CC(C)(C)OC(=O)N1CCC(Oc2ccc3oc(C(=O)O)cc3c2)C1

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.47
GPR119 Q8TDV5 4/20 0.46
PIM1 P11309 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
CHEK2 O96017 2/20 0.45
PIK3CD O00329 4/20 0.44
F10 P00742 3/20 0.43
F2 P00734 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16321103 0.87 PIM1 (0.45) USP30GPR119PIM1HRH3
SCHEMBL15171748 0.87 PIM1 (0.45) USP30GPR119PIM1HRH3
SCHEMBL29276822 0.81 GPR119 (0.52) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL31031682 0.81 GPR119 (0.52) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL29276820 0.81 GPR119 (0.52) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL30718557 0.80 USP30 (0.53) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL30718575 0.80 USP30 (0.53) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL27145612 0.80 USP30 (0.53) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL27143087 0.80 USP30 (0.53) USP30GPR119HRH3CHEK2PIK3CD
SCHEMBL27141850 0.80 USP30 (0.53) USP30GPR119HRH3CHEK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB USP30 587/4885GPR119 3723/4885PIM1 1555/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB USP30 590/4885GPR119 3741/4885PIM1 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.